Thursday, August 28, 2014
Inquirer Daily News

Daniel Hoffman

The un-free market for prescription drugs

Friday, April 12, 2013, 9:38 AM
To no one's surprise a large, multinational study published this month concluded that the per capita price for branded drugs in the US is as much as double what other advanced countries pay. The researchers from the London School of Economics and Johns Hopkins University looked at US prices for branded... Read more

When the market on Pharma stocks contradicts fundamentals

Friday, April 5, 2013, 7:00 AM
Hardly a day goes by without the stock prices of one or more Big Pharma companies reaching a 52-week high. Of the nine Big Cap pharmas covered by Sanford Bernstein, they rate six as Outperform (i.e., Buy) and three as Market-Perform (amounting to Hold). Also this week Citigroup reported that in... Read more

If markets are so great, try one for Pharma and Medicare

Thursday, March 28, 2013, 6:00 AM
In 2003 Gerard Anderson of Johns Hopkins University and Uwe Reinhardt from Princeton, together with two of their colleagues, published a study that concluded Americans pay health care costs that are as much as four times higher per person than other advanced countries. Just this week, the International... Read more

Not so far from selling medicine in Conestoga Wagons

Wednesday, March 20, 2013, 6:00 AM
An email from a reader last week contained a link to an article (see here) about the FDA's proposal to ease the efficacy and safety standards for approving new Alzheimer's drugs. His terse comment was, "If it goes through, it will open great opportunities for snake oil salesmen." His brief remark... Read more

How big pharma discourages innovation

Monday, March 4, 2013, 9:50 AM
Big Pharma has been keeping itself afloat for some time on a number of myths. For several years, as investors saw the industry's business model breaking down, pharma tried to assuage them by perpetrating the myth that the emerging global markets (China, India, Russia) will restore earlier profit levels... Read more

How to make pharma companies into law abiding citizens

Tuesday, February 19, 2013, 9:00 AM
Last summer UC Berkeley professor Robert Reich reflected on the $3 billion penalty GlaxoSmithKline (GSK) paid for a whole range of violations. Their criminal behavior that led to the fine included: promoting an antidepressant approved only for adults to kids under 18; selling two other antidepressants... Read more

Clinical R&D deserves more due diligence

Monday, February 11, 2013, 12:01 PM
Late last month Citigroup published its 2013 overview for pharma, "Global Healthcare Road Ahead: 2013 Outlook." It constitutes a sobering counterview to the touts and boosters from those in the investment community who tried to prop up the recent earnings reports. The critical challenge for pharma... Read more

Pharma's clinical development at cross purposes with itself

Tuesday, January 22, 2013, 9:00 AM
Developing new products through clinical trials represents the lifeblood of branded pharmaceuticals. Unless companies can develop new products to replace the existing ones that lose patent protection, their revenues will erode as payers and patients fill prescriptions with less expensive generics... Read more

Social networks among trial sites set the pace of patient recruitment

Tuesday, January 8, 2013, 9:00 AM
Last October we reviewed some KMR data, combined it with our own findings (see here) and concluded that while the industry's overall productivity at developing new drugs has not substantially changed during the past decade, the period between starting a compound's clinical trials and its registration... Read more

Pharma facts 2012: Behind the curve on important health care changes

Saturday, January 5, 2013, 10:00 AM
Editor’s Note: All this week Check Up will be sharing one new Pharma fact a day that was an important breakthrough in the world of pharmaceuticals in 2012. Today, Check Up delves into health care changes. One of this year's memorable expressions came from a wise fellow at a major software company... Read more
About this blog

Check Up covers major health events in our region and offers everything from personal health advice to an expert look at health reform. Read about some of our bloggers here.

For Portions of this blog may also be found in the Inquirer's Sunday Health Section

Michael R. Cohen, R.Ph. President, Institute for Safe Medication Practices
Daniel R. Hoffman, Ph.D. President, Pharmaceutical Business Research Associates
Also on
Stay Connected